Marshall Mazepa

@GeorgeGoshuaMD What happens when a patient dies from iTTP and doesn’t receive this therapy? The argument that you are on a crusade to lower drug costs will not hold legal water. Prepare for major liability

@GeorgeGoshuaMD If by “power of the prescription pad” you mean withhold this treatment, I think you are really playing with fire. You have an FDA approved therapy that likely reduces mortality and you advise withholding because of cost?

TWEETORIAL and @Blood 🚨: Caplacizumab in TTP has many lessons. Please RT if you learn something below. I hope we can have more nuanced discussions about this drug. Manuscript: doi.org/10.1182/blood.… Commentary by the inspirational Dr. Chaturvedi: doi.org/10.1182/blood.…

Outstanding commentary by James George, the King of TTP, on the Coppo paper of the French cohort. Can we really be looking at managing TTP without plasma exchange? If you manage patients with TTP you must read this short commentary. #TTP tinyurl.com/ynxof7me

Is plasma exchange still needed for #TTP? A thought provoking commentary on the future of the field by Dr. James George. A must read for anyone who treats this devastating condition

Excellent study by Coppo and colleagues: triplet therapy with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated #TTP in @BloodJournal #hemetwitter #TMA ashpublications.org/blood/article/…

Outstanding work! Congrats @LinaYoussef17 @JezidMiranda @Miki_blasco @FatimaCrispi and team! #complementbiology #preeclampsia #hellp

How it started: Eculizumab for the treatment of preeclampsia/HELLP syndrome. pubmed.ncbi.nlm.nih.gov/23228435/ How it’s going: Complement regulation to undo systemic harm in preeclampsia. The CRUSH trial. clinicaltrials.gov/ct2/show/NCT04…

Need a refresher?: Check out our #TTP review article in the Journal of Clinical Medicine. Glad I got to work with the illustrious #BerhardLammle and #SperoCataland. Now I just need to get them on Twitter! #hematology #medtwitter #MedEd @MDPIOpenAccess mdpi.com/2077-0383/10/3…

Join us for our January 🩸Blood Club🩸: HEREDITARY TTP: 1972 TO 2021 AND BEYOND, featuring Dr Jim George from @UofOklahoma!

Tune in now to check out the #ASH20 Poster Walk, featuring selected abstracts in #Hemostasis and #Thrombosis including our work on a Relapse Prediction Model for TTP patients! ⁦@ASH_hematology⁩ #ASHTrainee ativsoftware.com/appinfo.php?pa… #ASH20

It seems the UK data are instructive in early use being potentially critical in seeing a mortality benefit

Our meeting videos are up at: ustmaconsortium.com/2020pm !

Amazing to be part of this free virtual meeting for patients today. @USTMAConsortium has come a long way since initial inception, lead by @ttpdoc and Spero Cataland. Thank you for spearheading this and for allowing us to be a part of this.

@heme_fan @USTMAConsortium Thanks for joining us! It’s so exciting to host this event for patients!

Finally, we have the up-to-date guidance document on #ADAMTS13 assays published ahead of print #OpenAccess. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of ADAMTS13 onlinelibrary.wiley.com/doi/full/10.11…

The #Thrombotic #Microangiopathies State-of-the-Art Session will host Drs. Giuseppe Remuzzi @DrXLongZheng,@MarcelLevi to provide recent advances in diagnosis/therapies of TM. Come to the #ISTH2020 Virtual Meeting Room 2, Sunday, July 12, 2020, 08:45 – 10:00. #ADAMTS13, #TTP

ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP ow.ly/z7Qa50AtSst

Join us 8/22 for our virtual meeting. Register for free at ustmaconsortium.com

@SocietyHospMed @JHospMedicine @SamirShahMD @andrewolsonmd It was a tricky and fun one to contribute to! Thanks for including me!

NEW @JHospMedicine's Editor's Pick (@SamirShahMD) 📚 Clinical Care Conundrums: A Fiery Pivot 💻 Log in to access the full piece here: fal.cn/38GeS Thank you to our contributors: R Cole Pueringer, MD, @andrewolsonmd, Marshall Mazepa, MD, Samuel T Ives, MD